| CAS ID: | 220127-57-1 |
| Molecular Formula: | C30H35N7O4S |
| Molecular Weight: | 493.6 g/mol |
| Monoisotopic Mass: | 493.259 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | GLIVEC | GLEEVEC | IMATINIB MESILATE | IMATINIB MESYLATE | STI 571 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4) | See All |
| InChI Key: | YLMAHDNUQAMNNX-UHFFFAOYSA-N | |
| Smiles: | CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1.CS(=O)(=O)O | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT00981942 | Disease | Nephrogenic systemic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | September 22, 2009 | Last Verified | June 5, 2012 |
| Sponsor | University of Aarhus | ||
Trial Record 2
| ClinicalTrial ID | NCT00677092 | Disease | Nephrogenic systemic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | May 13, 2008 | Last Verified | May 19, 2017 |
| Sponsor | Massachusetts General Hospital | ||
Trial Record 3
| ClinicalTrial ID | NCT00131274 | Disease | Idiopathic pulmonary fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | August 18, 2005 | Last Verified | October 5, 2005 |
| Sponsor | Daniels, Craig E., M.D. | ||
Trial Record 4
| ClinicalTrial ID | NCT00613171 | Disease | Systemic sclerosis |
| Phase | Phase 2 | Status | Completed |
| First Received | February 12, 2008 | Last Verified | October 10, 2018 |
| Sponsor | Novartis Pharmaceuticals | ||
| PubChem: | 90091706 |
| ChEMBL: | CHEMBL1642 |